Stocktoria
IMMUCELL CORP /DE/ ICCC
IMMUCELL CORP /DE/ (ICCC) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $27.6M at a -3.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.09 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.305 |
| Retained earnings / assets | -0.357 |
| EBIT / assets | 0.039 |
| Equity / liabilities | 1.748 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ICCC | IMMUCELL CORP /DE/ | 6/9 | 2.93 | — | +4.3% |
| TKNO | Alpha Teknova, Inc. | 5/9 | -1.59 | — | +7.4% |
| NNNN | Anbio Biotechnology | 4/9 | — | 326.5 | — |
| BMRA | BIOMERICA INC | 2/9 | — | — | — |
| IMDX | Insight Molecular Diagnostics Inc. | 3/9 | — | — | — |
| CLDX | Celldex Therapeutics, Inc. | 1/9 | 1.9 | — | — |
| CDIO | Cardio Diagnostics Holdings, Inc. | 1/9 | -4.17 | — | — |
About IMMUCELL CORP /DE/
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.
FAQ
Is ICCC financially healthy?
IMMUCELL CORP /DE/'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does ICCC pay a dividend?
No, IMMUCELL CORP /DE/ does not currently pay a dividend.
How profitable is ICCC?
In FY2025, IMMUCELL CORP /DE/ had a net margin of -3.8% and a return on equity of -3.8%.
Is ICCC overvalued or undervalued?
IMMUCELL CORP /DE/ trades at about 91.5× trailing earnings — below its 10-year norm (10-year range 15.4×–127.7×, median 107.2×). Stocktoria reports the data, not buy/sell advice.
Is ICCC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on IMMUCELL CORP /DE/: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.